✨ Free AI Report
Cyclomics: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cyclomics
Company Research

Cyclomics: Business Overview, Financials & Competitive Analysis

Cyclomics scores 6/10 on the AskCyborg Cyborg Score (Solid). Innovative liquid biopsy platform with regulatory potential in underserved cancer diagnostics market, but execution and funding runway remain key execution risks. Cyclomics has a proprietary, published technology with significant academic backing, strategic partnerships with Oxford Nanopore, and demonstrated clinical applications. However, the failed acquisition attempt in early 2026 and private funding.

What is Cyclomics's industry? Cyclomics (cyclomics.com) operates in In-Vitro Diagnostics. AskCyborg classifies Cyclomics under In-Vitro Diagnostics in its company registry.

Cyclomics is a Dutch startup founded in 2018 by scientists of UMC Utrecht, transforming cancer care by enabling faster and more reliable diagnoses, particularly in cancer recurrence detection. The company's CyclomicsS...

6/ 10Solid

Cyborg Score thesis

Innovative liquid biopsy platform with regulatory potential in underserved cancer diagnostics market, but execution and funding...

Read the full analyst-debate transcript →
Industry In-Vitro Diagnostics
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cyclomics Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Cyclomics

AskCyborg analysts argue the bull and bear cases for Cyclomics across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cyclomics OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Cyclomics Overview

Pro stress-test →

Cyclomics is a Dutch startup founded in 2018 by scientists of UMC Utrecht, transforming cancer care by enabling faster and more reliable diagnoses, particularly in cancer recurrence detection. The company's CyclomicsSeq consensus sequencing approach improves Oxford Nanopore sequencing quality by 60-fold, enabling detection of rare mutations in blood of cancer patients.

Strategic Profile

Pro stress-test →

Cyclomics has developed cutting-edge technology for detecting circulating tumor DNA using 3rd generation Nanopore sequencers, enabling fast, low-cost, point-of-care sequencing with nearly 100% accuracy to detect single ctDNA molecules. The company launched its services branch, expanding its technology and expertise into life sciences, biotechnology, genomics, and clinical diagnostics.

Competitive Landscape

Pro stress-test →

Cyclomics serves hospitals and cancer treatment centers requiring reliable diagnostic tools. Direct competitors include Guardant Health and Foundation Medicine in ctDNA-based cancer monitoring, while broader competitors span liquid biopsy platforms (Illumina, BGI) and genomics diagnostics companies (Tempus, Invitae). Cyclomics differentiates through proprietary rolling circle amplification-based nanopore sequencing and faster turnaround (90-minute tumor classification capability).

Industry Context

Cyclomics operates in In-Vitro Diagnostics.

Key facts

Founded: 2018 · Headquarters: Utrecht, Netherlands · Employees: N/A · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cyclomics.

  • Accepted into Google Cloud Startup Program to support computational needs for big data and AI model training
  • Published NanoRCS technology in Genome Research showcasing enhanced genome-wide ctDNA sequencing for ultra-sensitive, cost-effective cancer detection
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Early 2026GEDiCube acquisition fell through; independent growth strategy resumed
  • 2025Google Cloud Startup Program acceptance for AI/ML computational infrastructure
  • +2 moreTrack every material event for Cyclomics as it happens. Explore monitoring →
Get alerted when Cyclomics has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Guardant HealthLeading ctDNA-based cancer detection and monitoring platform→Foundation MedicinePrecision oncology genomics for cancer diagnosis and treatment→GRAIL (Galleri)Multi-cancer early detection blood test→TempusAI-powered genomics and molecular diagnostics→

Compare Cyclomics with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cyclomics operates in In-Vitro Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse In-Vitro Diagnostics research →
NEW · MCP server

Ask your AI assistant about Cyclomics

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cyclomics and its top competitor on Cyborg Score”
“What did Cyclomics do this quarter?”
“Is Cyclomics a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cyclomics do?+
Cyclomics is a Dutch startup founded in 2018 by scientists of UMC Utrecht, transforming cancer care by enabling faster and more reliable diagnoses, particularly in cancer recurrence detection. The company's CyclomicsS...
What is Cyclomics's Cyborg Score?+
Cyclomics has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cyclomics's main competitors?+
Named competitors include Guardant Health, Foundation Medicine, GRAIL (Galleri), Tempus. The full competitive landscape is in the AskCyborg report.
How can I get the full Cyclomics research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cyclomics research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cyclomics over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More In-Vitro Diagnostics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7DiaSorin S.p.A.7Shenzhen New Industries Biomedical Engineering Co., Ltd.4Biosynex SA